Issue 34 - Aug 9, 2019
Issue 31 - Aug 2, 2019
  • Conversation with The Cancer Letter

    Sylvester becomes 71st NCI-designated cancer center

    After six years of aggressively recruiting and spending more than $250 million to build up its programs, Sylvester Comprehensive Cancer Center has become the 71st NCI-designated cancer center in the US and the only such institution in South Florida.

  • MD Anderson retains top spot on U.S. News rankings; Johns Hopkins moves up to No. 4

    U.S. News & World Report rankings for 2019-20 significantly reshuffled the top 10 best cancer hospitals, with Johns Hopkins, UPMC, Massachusetts General, and Northwestern moving up the list.

  • In Brief

    • AACR announces new journal, Blood Cancer Discovery
    • Strata Oncology partners with five additional health systems
    • ACS CAN report: Texas must improve cancer-related public policies
    • TCR2 Therapeutics partners with NCI for phase I/II trial of TC-210
  • TCCL Logo

  • Trials & Tribulations

    Barriers to clinical trial enrollment

    Part I of a two-part series

    According to the National Cancer Institute (NCI), 1,735,350 people were newly diagnosed with cancer in 2018. Of those, 65% are expected to achieve remission from their cancer 1. While most physicians agree that clinical trials advance medical knowledge and improve treatment, estimates as low as 2 – 3% of cancer patients enter clinical trials annually 2, 3. Physician knowledge of available clinical trials at their site, training in communication skills and administering clinical trials, and time constraints during patient care time have all been identified as barriers to clinical trial enrollment 1. In addition, strict eligibility criteria and inadequate insurance coverage for required tests may also hinder enrollment.

  • Drugs & Targets

    • FDA approves darolutamide for non-metastatic castration-resistant prostate cancer
    • FDA grants breakthrough designation for NKTR-214 in combination with nivolumab for melanoma
    • EMA adopts positive opinion for Keytruda + Inlyta as first-line for RCC
  • NCI Trials

    NCI Trials for August

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

Issue 30 - Jul 26, 2019